Alex has a background that melds scientific innovation in biopharma with corporate development. He started his career on the scientific side at Sutro Biopharma where he helped develop a cell-free protein expression system. Holding a variety of positions over the years, Alex has led multiple drug discovery projects in the immuno-oncology and antibody-drug conjugate space, before transitioning to Corporate Strategy and BD. Alex is experienced in executing complex drug licensing arrangements and discovery collaboration deals.

Alex received his MBA from The Wharton School as a Palmer Scholar and holds both a B.S. and M.S. in Chemical Engineering from Stanford University, where he was awarded the Frederick Emmons Terman Engineering Scholastic Award and Hoefer Prize in writing.